Drug Type Monoclonal antibody |
Synonyms SRB3-43 |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Preclinical | Chile | 30 Jan 2022 | |
Neoplasms | Preclinical | Spain | - |